← Issue №18/ week of Nov 1, 2026/Pancreas/Biliary

IgG4-related autoimmune pancreatitis: a journey.

From GI Signals issue №18: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Pancreas/Biliary review · Oct 26, 2026 · Pancreatology · IF 3.0

IgG4-related autoimmune pancreatitis: a journey.

New therapyautoimmune pancreatitisbiomarkertranslationalbasic science
Clinical takeawayNo clinical action from this historical review: it reports no trial results and does not compare CD19-targeted agents with corticosteroids.
What it foundThe review traces IgG4-related disease and type 1 autoimmune pancreatitis from early case descriptions through the 2011 international consensus criteria to CD19-targeted agents tested in the MITIGATE and INDIGO trials, and discusses FAPI-PET and cancer risk.
ContextThis review highlights the evolution of IgG4-RD treatment from corticosteroids to targeted therapies, aligning with current practice trends.
Emergingsuggested applicable standard· American College of Gastroenterology, 'ACG Clinical Guideline: Chronic Pancreatitis' (Gardner TB et al., Am J Gastroenterol 2020;115(3):322-339). DOI 10.14309/ajg.0000000000000535, PMID 32022720.

… Screen for PDAC per lifetime risk and pursue etiologic workup via TIGAR-O v2, including genetic testing and autoimmune pancreatitis evaluation.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Confirm chronic pancreatitis on CROSS-SECTIONAL IMAGING, CT for late calcific disease, MRI/MRCP (with secretin where available) for earlier ductal and parenchymal change, EUS an acceptable alternative; per ACG 2020, "Diagnosis is made usually on cross-sectional imaging, with modalities such as endoscopic ultrasonography and pancreatic function tests playing a secondary role". Fecal elastase does NOT confirm chronic pancreatitis: it is a test of exocrine FUNCTION and is the appropriate initial test for the exocrine pancreatic insufficiency (EPI) that chronic pancreatitis causes, a consequence of the disease, not the diagnosis of it. A normal fecal elastase does not exclude chronic pancreatitis and a low one does not establish it. Per AGA 2023, fecal elastase must be run on a semi-solid or solid stool specimen; below 100 mcg/g is good evidence of EPI and 100-200 mcg/g is indeterminate (below 200 mcg/g is the cutoff commonly used to screen). Then manage with smoking and alcohol cessation, PERT for exocrine insufficiency titrated to symptoms, fat-soluble vitamin and bone surveillance, and individualized type 3c diabetes control, considering insulin early in patients with marked hyperglycemia or symptoms of insulin deficiency. Treat pain with a stepwise ladder from scheduled acetaminophen and neuromodulators to EUS-guided celiac plexus block and endoscopic/surgical intervention, referring early for surgery per ESCAPE 2020 in candidates with main pancreatic duct obstruction. Screen for PDAC per lifetime risk and pursue etiologic workup via TIGAR-O v2, including genetic testing and autoimmune pancreatitis evaluation.

American College of Gastroenterology, 'ACG Clinical Guideline: Chronic Pancreatitis' (Gardner TB et al., Am J Gastroenterol 2020;115(3):322-339). DOI 10.14309/ajg.0000000000000535, PMID 32022720. · reviewed 2026-07-21 ↗
Löhr JM · Pancreatology : Official Journal of the International Association of Pancreatology (IAP) .. [et Al.] · IF 3.0 · PubMed ↗Permalink
← Read the whole of issue №18 Every paper GI Signals surfaces gets a page like this one. All issues